Prothya Biosolutions: Clinical Trials

7 trials sponsored by Prothya Biosolutions, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 active not recruiting, 1 terminated, 1 unknown. 7 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 47Completed 4, Active not recruiting 1, Terminated 1, Unknown 1

Follow Prothya Biosolutions: new trials by email

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Dupilumab - Atopic Dermatitis, Atopic Dermatitis Eczema
Phase 4Active not recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2162023-08-142026-10-29
Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS
Wide Excision, Adalimumab Injection - Hidradenitis Suppurativa
Phase 4UnknownErasmus Medical Center1282018-07-312019-02-08
C1-inhibitor in Allergic ASThma Patients
C1-inhibitor, Saline, Antibiotics - Asthma
Phase 4TerminatedT. van der Poll372016-11-162020-06-24
Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
Natalizumab - Multiple Sclerosis
Phase 4CompletedAmsterdam UMC, location VUmc612016-11-032019-07-12
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
intravenous immunoglobulins, antibiotics - IgG Deficiency, Infections
Phase 4CompletedProthya Biosolutions552007-11-012015-04-06
Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)
human coagulation Factor IX - Hemophilia B
Phase 4CompletedProthya Biosolutions122003-05-012007-08-30
Study Use of PPSB-SD and VP-VI in Patients With Anticoagulant Therapy and Undergoing Acute CPB Surgery
PPSB-SD - CPB, Oral Anticoagulant Therapy
Phase 4CompletedProthya Biosolutions402002-03-012023-12-07

Conditions studied

Angioedemas, Hereditary (1)  ·  Asthma (1)  ·  Dermatitis, Atopic (1)  ·  Hemophilia B (1)  ·  Hidradenitis Suppurativa (1)  ·  IgG Deficiency (1)  ·  Infections (1)  ·  Multiple Sclerosis (1)

Interventions

Anti-Bacterial Agents (2)  ·  Adalimumab (1)  ·  Ciprofloxacin (1)  ·  Complement C1 Inhibitor Protein (1)  ·  Factor IX (1)  ·  Immunoglobulins, Intravenous (1)  ·  Metronidazole (1)  ·  Natalizumab (1)  ·  SERPING1 protein, human (1)  ·  Sodium Chloride (1)  ·  Vancomycin (1)  ·  dupilumab (1)

Countries

Netherlands (6)  ·  Belgium (1)

Top investigators

DirkJan Hijnen, MD PhD (1)  ·  E AM Sanders, PhD, MD (1)  ·  E P Mauser-Bunschoten, MD, PdD (1)  ·  J T van Dissel, PhD, MD (1)  ·  Joep Killestein, Dr. (1)  ·  Louise AA Gerbens, MD PhD (1)  ·  Martijn van Doorn, MD, PhD (1)  ·  P FW Strengers, MD (1)  ·  Phyllis I Spuls, MD PhD (1)  ·  T W Kuijpers, PhD, MD (1)

Results publications

PMID 34303860

NIH funding

2023 (1)